Press release
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN,
About this update from Natera, Inc.
[{"type":"text","content":"Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study \nAUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.\n\n \n \n \n \n \n \n\n \nSignatera data was presented in 4 abstracts, including both oral and poster presentations. These include results from a real-world study on colorectal cancer (CRC) patients as well as an early readout from the BELLINI trial that highlights how circulating tumor DNA (ctDNA) dynamics can help inform neoadjuvant treatment decision-making in hormone receptor negative, HER2 negative (triple-negative) breast cancer (TNBC). The key highlights are below:\nAbstract # 1828 | Late-Breaking Oral Presentation | Presenter: Marleen Kok\nNivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial\nThis study evaluates the potential clinical utility of ctDNA in assessing the response to neoadjuvant immunotherapy in patients with early stage (I-II) TNBC. Thirty patients were treated with two cycles of the immune checkpoint inhibitor (ICI) nivolumab, alone or in combination with ipilimumab, prior to the start of neoadjuvant chemotherapy. Response to ICIs was evaluated radiographically, as well as through the analysis of ctDNA dynamics. All of the patients who achieved partial response by imaging presented with 50-100% reduction in ctDNA levels compared to pretreatment, while increasing or stable ctDNA levels were observed in non-responders.\n\"The BELLINI trial supports MRD testing for early, reliable immunotherapy response monitoring in the neoadjuvant TNBC setting,\" said Dr. Minetta Liu, Natera's chief medical officer of oncology. \"We are very encouraged by the data generated through our collaboration with Dr. Kok and colleagues, and we look forward to ongoing work to push the boundaries of chemotherapy de-escalation.\"\nAbstract # 319MO | Mini Oral Presentation | Presenter: Stacey A. Cohen\nReal world monitoring of circulating tumor...